A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia

Gynecologic Oncology

Volumn 138, Issue 1, 2015, Pages 55-61

  Hirte, H ^a   Lheureux, S ^b   Fleming, G F ^c   Sugimoto, A ^d   Morgan, R ^e   Biagi, J ^f   Wang, L ^b   McGill, S ^b   Ivy, S P ^g   Oza, A M ^b  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f Cancer Centre of Southeastern Ontario   (Canada)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cediranib; Ovarian cancer; Phase 2; Recurrence

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CA 125 ANTIGEN; CEDIRANIB; LIVER ENZYME; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; EPISTAXIS; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATURIA; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; ORAL MUCOSITIS; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECTUM HEMORRHAGE; SIDE EFFECT; STOMACH OBSTRUCTION; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; VAGINA DISEASE; VOICE CHANGE; CLINICAL TRIAL; FALLOPIAN TUBE NEOPLASMS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORAL DRUG ADMINISTRATION; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TUMOR RECURRENCE; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; QUINAZOLINES;

EID: 84931569778     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.04.009     Document Type: Article

References (37)

1. W.P. McGuire, and R.S. Ozols Chemotherapy of advanced ovarian cancer Semin. Oncol. 25 1998 340 348
2. B.J. Monk, H. Dalton, and J.H. Farley Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer Crit. Rev. Oncol. Hematol. 86 2 May 2013 161 175
3. R.A. Burger, M.W. Sill, and B.J. Monk Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study J. Clin. Oncol. 25 2007 5165 5171
4. S.A. Cannistra, U.A. Matulonis, and R.T. Penson Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J. Clin. Oncol. 25 2007 5180 5186
5. R.A. Burger, M.F. Brady, and M.A. Bookman Incorporation of bevacizumab in the primary treatment of ovarian cancer N. Engl. J. Med. 365 26 Dec 29 2011 2473 2483
6. T.J. Perren, A.M. Swart, and J. Pfisterer A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 365 26 Dec 29 2011 2484 2496
7. A.M. Oza, T.J. Perren, and A.M. Swart Late breaking abstract: ICON7: final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer Abstract Number: 6 European Cancer Congress 2013
8. C. Aghajanian, S.V. Blank, and B.A. Goff OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J. Clin. Oncol. 30 17 Jun 10 2012 2039 2045
9. E. Pujade-Lauraine, F. Hilpert, and B. Weber Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial J. Clin. Oncol. 32 13 May 1 2014 1302 1308
10. H.W. Hirte Novel developments in angiogenesis cancer therapy Curr. Oncol. 16 3 May 2009 50 54
11. M. Sahade, F. Caparelli, and P.M. Hoff Cediranib: a VEGF receptor tyrosine kinase inhibitor Future Oncol. 8 7 Jul 2012 775 781
12. J. Drevs, P. Siegert, and M. Medinger Phase I clinical study of cediranib, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors J. Clin. Oncol. 25 2007 3045 3054
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J. Natl. Cancer Inst. 92 3 2000 205 216
14. G.J. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J. Clin. Oncol. 21 10 Suppl. May 15 2003 187s 193s
15. R. Simon Optimal two-stage designs for phase II clinical trials Control. Clin. Trials 10 1989 1 10
16. U.A. Matulonis, S. Berlin, and P. Ivy Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J. Clin. Oncol. 27 2009 5601 5606
17. J.A. Ledermann, T. Perren, F.A. Raja, and et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial Eur. J. Cancer XX 2013 (suppl.: LBA 10)
18. J.F. Liu, W.T. Barry, and M. Birrer Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomized phase 2 study Lancet Oncol. 15 11 Oct 2014 1207 1214
19. J. Holash, S. Davis, and N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc. Natl. Acad. Sci. U. S. A. 99 17 2002 11393 11398
20. W.H. Gotlieb, F. Amant, and S. Advani Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study Lancet Oncol. 13 2012 154 162
21. W.P. Tew, N. Colombo, and I. Ray-Coquard Intravenousaflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study Cancer 120 3 Feb 1 2014 335 343
22. O. Hahn, and W. Stadler Sorafenib Curr. Opin. Oncol. 18 2006 615 621
23. D. Matei, M.W. Sill, and H.A. Lankes Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial J. Clin. Oncol. 29 1 Jan 1 2011 69 75
24. T.J. Herzog, G. Scambia, and B.G. Kim A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma Gynecol. Oncol. 130 1 Jul 2013 25 30
25. L.Q.M. Chow, and S.G. Eckhardt Sunitinib: from rational design to clinical efficacy J. Clin. Oncol. 25 7 2007 884 896
26. S.M. Campos, R.T. Penson, and U. Matulonis A phase II trial of sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma Gynecol. Oncol. 7 2013 215 220
27. K.H. Baumann, A. du Bois, and W. Meier A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy Ann. Oncol. 23 9 Sep 2012 2265 2271
28. J.J. Biagi, A.M. Oza, and H.I. Chalchal A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC clinical trials group study Ann. Oncol. 22 2 Feb 2011 335 340
29. F. Hilberg, G.J. Roth, and M. Krssak BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy Cancer Res. 68 2008 4774 4782
30. J.A. Ledermann, A. Hackshaw, and S. Kaye Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer J. Clin. Oncol. 29 2011 3798 3804
31. A. Du Bois, G. Kristensen, and I. Ray-Coquard AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer [abstract] Int. J. Gynecol. Cancer 7 Suppl. 1 2013 LBA1
32. G. Sonpavde, T.E. Hutson, and C.N. Sternberg Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma Expert Opin. Investig. Drugs 17 2008 253 261
33. M. Friedlander, K.C. Hancock, and D. Rischin A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer Gynecol. Oncol. 119 2010 32 37
34. A. du Bois, A. Floquet, and J.W. Kim Incorporation of pazopanib in maintenance therapy of ovarian cancer J. Clin. Oncol. 32 30 Oct 20 2014 3374 3382
35. A. Coxon, J. Bready, and H. Min Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody Mol. Cancer Ther. 9 10 Oct 2010 2641 2651
36. B.J. Monk, A. Poveda, and I. Vergote Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial Lancet Oncol. 15 8 Jul 2014 799 808
37. J.F. Liu, and S.A. Cannistra Emerging role for bevacizumab in combination with chemotherapy for patients with platinum-resistant ovarian cancer J. Clin. Oncol. 32 13 May 1 2014 1287 1289